Lyka Labs — 360° view

Lyka Labs, a company in the Pharmaceuticals industry, reported revenue of ₹44 crore and net profit of ₹1.27 crore for the September 2026 quarter.

Lyka Labs (NSE: LYKALABS-BE) closed at ₹93.41 on 20 Nov 2026. Its market capitalisation is ₹338 crore.

Share price
₹93.41 (20 Nov 2026)
Market cap
₹338 Cr (20 Nov 2026)
Revenue
₹44 Cr (September 2026 quarter)
Net profit
₹1 Cr (September 2026 quarter)
ROCE
-5.98% (FY26)
ROE
-10.2% (FY26)
Book value
₹26.5 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹93.41 / ₹58.00 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: LYKALABS-BE

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.